サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434320

節足動物媒介性ウイルス感染症検査市場：検査タイプ別、エンドユーザー別-2024-2030年の世界予測

Arthropod-borne Viral Infections Testing Market by Test Type (Cultural Tests, Immunoassays, Molecular Tests), End-user (Diagnostic Centers, Hospitals, Research Centers) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
節足動物媒介性ウイルス感染症検査市場：検査タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

節足動物媒介性ウイルス感染症検査市場規模は2023年に109億9,000万米ドルと推計され、2024年には121億8,000万米ドルに達し、CAGR 10.88%で2030年には226億6,000万米ドルに達すると予測されます。

節足動物媒介性ウイルス感染症検査の世界市場

主な市場の統計
基準年[2023］ 109億9,000万米ドル
予測年[2024］ 121億8,000万米ドル
予測年 [2030] 226億6,000万米ドル
CAGR（%） 10.88%
節足動物媒介性ウイルス感染症検査 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは節足動物媒介性ウイルス感染症検査市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、節足動物媒介性ウイルス感染症検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-節足動物媒介性ウイルス感染症検査市場の市場規模および予測は？

2-節足動物媒介性ウイルス感染症検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-節足動物媒介性ウイルス感染症検査市場における技術動向と規制の枠組みは？

4-節足動物媒介性ウイルス感染症検査市場における主要ベンダーの市場シェアは？

5-節足動物媒介性ウイルス感染症検査市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 節足動物媒介性ウイルス感染症の増加
      • 節足動物媒介性ウイルス診断の改善
      • アルボウイルス感染症に関する政府の取り組みと啓発キャンペーン
    • 抑制要因
      • 節足動物媒介性ウイルス感染症診断キットの製品リコール発生率
    • 機会
      • ELISAベースの検査診断の受け入れが増加
      • 試験方法の技術進歩
    • 課題
      • 調査研究やワクチン開発のためのアルボウイルス動物モデルの開発の難しさ
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 節足動物媒介性ウイルス感染症検査市場：検査タイプ別

  • 文化試験
  • 免疫学的検査
  • 分子検査

第7章 節足動物媒介性ウイルス感染症検査市場：エンドユーザー別

  • 診断センター
  • 病院
  • 研究センター

第8章 南北アメリカの節足動物媒介性ウイルス感染症検査市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の節足動物媒介性ウイルス感染症検査市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの節足動物媒介性ウイルス感染症検査市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Abnova Corporation
    • ACROBiosystems
    • AdvaCare Pharma
    • ARUP Laboratories
    • Bio Lab Diagnostics（I）Private Limited
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne
    • BIOGENIX INC. PVT. LTD.
    • bioMerieux SA
    • Chembio Diagnostics, Inc.
    • Clongen Laboratories, LLC
    • Coppe Laboratories
    • EIKEN CHEMICAL Co., Ltd.
    • Elabscience Biotechnology Inc.
    • EUROIMMUN AG by PerkinElmer Inc.
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc.
    • InBios International, Inc.
    • J Mitra & Co Ltd
    • Kephera Diagnostics
    • Merck KGaA
    • Quest Diagnostics Incorporated
    • Sonora Quest Laboratories LLC
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET DYNAMICS
  • FIGURE 7. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CULTURAL TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 10. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 100. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET LICENSE & PRICING
目次
Product Code: MRR-4103B31E09D4

[193 Pages Report] The Arthropod-borne Viral Infections Testing Market size was estimated at USD 10.99 billion in 2023 and expected to reach USD 12.18 billion in 2024, at a CAGR 10.88% to reach USD 22.66 billion by 2030.

Global Arthropod-borne Viral Infections Testing Market

KEY MARKET STATISTICS
Base Year [2023] USD 10.99 billion
Estimated Year [2024] USD 12.18 billion
Forecast Year [2030] USD 22.66 billion
CAGR (%) 10.88%
Arthropod-borne Viral Infections Testing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Arthropod-borne Viral Infections Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Arthropod-borne Viral Infections Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Arthropod-borne Viral Infections Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, ACROBiosystems, AdvaCare Pharma, ARUP Laboratories, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Bio-Techne, BIOGENIX INC. PVT. LTD., bioMerieux SA, Chembio Diagnostics, Inc., Clongen Laboratories, LLC, Coppe Laboratories, EIKEN CHEMICAL Co., Ltd., Elabscience Biotechnology Inc., EUROIMMUN AG by PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Hologic, Inc., InBios International, Inc., J Mitra & Co Ltd, Kephera Diagnostics, Merck KGaA, Quest Diagnostics Incorporated, Sonora Quest Laboratories LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Arthropod-borne Viral Infections Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Test Type
    • Cultural Tests
    • Immunoassays
    • Molecular Tests
  • End-user
    • Diagnostic Centers
    • Hospitals
    • Research Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Arthropod-borne Viral Infections Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Arthropod-borne Viral Infections Testing Market?

3. What are the technology trends and regulatory frameworks in the Arthropod-borne Viral Infections Testing Market?

4. What is the market share of the leading vendors in the Arthropod-borne Viral Infections Testing Market?

5. Which modes and strategic moves are suitable for entering the Arthropod-borne Viral Infections Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Arthropod-borne Viral Infections Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing arthropod-borne viral infections
      • 5.1.1.2. Improvements in arthropod-borne viral diagnostics
      • 5.1.1.3. Government initiatives and awareness campaigns regarding arboviral infections
    • 5.1.2. Restraints
      • 5.1.2.1. Product recall incidences of arthropod-borne viral infections diagnostic kits
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising acceptance of ELISA-based test diagnostics
      • 5.1.3.2. Technological advancements in testing methods
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulties in developing arbovirus animal models for research study and vaccine development
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Arthropod-borne Viral Infections Testing Market, by Test Type

  • 6.1. Introduction
  • 6.2. Cultural Tests
  • 6.3. Immunoassays
  • 6.4. Molecular Tests

7. Arthropod-borne Viral Infections Testing Market, by End-user

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals
  • 7.4. Research Centers

8. Americas Arthropod-borne Viral Infections Testing Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Arthropod-borne Viral Infections Testing Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Abnova Corporation
    • 12.1.3. ACROBiosystems
    • 12.1.4. AdvaCare Pharma
    • 12.1.5. ARUP Laboratories
    • 12.1.6. Bio Lab Diagnostics (I) Private Limited
    • 12.1.7. Bio-Rad Laboratories, Inc.
    • 12.1.8. Bio-Techne
    • 12.1.9. BIOGENIX INC. PVT. LTD.
    • 12.1.10. bioMerieux SA
    • 12.1.11. Chembio Diagnostics, Inc.
    • 12.1.12. Clongen Laboratories, LLC
    • 12.1.13. Coppe Laboratories
    • 12.1.14. EIKEN CHEMICAL Co., Ltd.
    • 12.1.15. Elabscience Biotechnology Inc.
    • 12.1.16. EUROIMMUN AG by PerkinElmer Inc.
    • 12.1.17. F. Hoffmann-La Roche Ltd
    • 12.1.18. Hologic, Inc.
    • 12.1.19. InBios International, Inc.
    • 12.1.20. J Mitra & Co Ltd
    • 12.1.21. Kephera Diagnostics
    • 12.1.22. Merck KGaA
    • 12.1.23. Quest Diagnostics Incorporated
    • 12.1.24. Sonora Quest Laboratories LLC
    • 12.1.25. Thermo Fisher Scientific Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing